

Freedom of Information Act 2000

The Royal Cornwall Hospitals NHS Trust Response to Information request

Date Request Received: 08 October 2025

FOI Ref 30601

Requested Information:

I am analysing the treatment of lung cancer and would greatly appreciate it if you could answer the following question:

Q1. How many non-small cell lung cancer (NSCLC) patients were treated in the past 3 months with:

- ALK Inhibitors (Alectinib, Brigatinib, Ceritinib, Crizotinib, Lorlatinib)
- Amivantamab Monotherapy
- Atezolizumab monotherapy (any formulation) OR Atezolizumab monotherapy (infusion only)
- Atezolizumab (any formulation) + Bevacizumab + Carboplatin + Paclitaxel
- Atezolizumab monotherapy (subcutaneous injection only)
- Dabrafenib + Trametinib
- Docetaxel monotherapy or in combination with Carboplatin/Cisplatin
- Durvalumab
- Gemcitabine
- Nintedanib + Docetaxel
- Nivolumab
- Osimertinib
- Other EGFR Inhibitors (Afatinib, Erlotinib, Gefitinib, Dacomitinib, Mobocertinib)
- Paclitaxel
- Pembrolizumab Monotherapy
- Pembrolizumab + Paclitaxel + Platinum (Carboplatin/Cisplatin)
- Pembrolizumab + Pemetrexed + Platinum (Carboplatin/Cisplatin)
- Pemetrexed + Platinum (Carboplatin/Cisplatin)
- RET Inhibitors (Pralsetinib, Selpercatinib)
- Sotorasib
- Tepotinib
- Vinorelbine monotherapy or in combination with Carboplatin/Cisplatin
- Other active systemic anti-cancer therapy
- Palliative care only

- Amivantamab with carboplatin and pemetrexed
- Cemiplimab with platinum-based chemotherapy
- Adagrasib
- Datopotamab deruxtecan
- Amivantamab with lazertinib

Q2. Does your trust participate in any clinical trials for Non-Small Cell Lung Cancer?
If so, please provide the name of each trial, and the number of patients taking part.

Response:

Q1. How many non-small cell lung cancer (NSCLC) patients were treated in the past 3 months with:

- ALK Inhibitors (Alectinib, Brigatinib, Ceritinib, Crizotinib, Lorlatinib) **8**
- Amivantamab Monotherapy **0**
- Atezolizumab monotherapy (any formulation) OR Atezolizumab monotherapy (infusion only) **4**
- Atezolizumab (any formulation) + Bevacizumab + Carboplatin + Paclitaxel **2**
- Atezolizumab monotherapy (subcutaneous injection only) **2**
- Dabrafenib + Trametinib **3**
- Docetaxel monotherapy or in combination with Carboplatin/Cisplatin **0**
- Durvalumab **13**
- Gemcitabine **0**
- Nintedanib + Docetaxel **1**
- Nivolumab **1 (with carboplatin + pemetrexed)**
- Osimertinib **25**
- Other EGFR Inhibitors (Afatinib, Erlotinib, Gefitinib, Dacomitinib, Mobocertinib) **2**
- Paclitaxel **0**
- Pembrolizumab Monotherapy **55 (29 of these are on pembrolizumab maintenance following pembrolizumab + induction chemotherapy)**
- Pembrolizumab + Paclitaxel + Platinum (Carboplatin/Cisplatin) **7**
- Pembrolizumab + Pemetrexed + Platinum (Carboplatin/Cisplatin) **16**
- Pemetrexed + Platinum (Carboplatin/Cisplatin) **3**
- RET Inhibitors (Pralsetinib, Selpercatinib) **0**

- Sotorasib **3**
- Tepotinib **2**
- Vinorelbine monotherapy or in combination with Carboplatin/Cisplatin **2**
- Other active systemic anti-cancer therapy – Carboplatin + Paclitaxel - **6**
- Palliative care only **5 1st treatment starts**
- Amivantamab with carboplatin and pemetrexed **0**
- Cemiplimab with platinum-based chemotherapy **0**
- Adagrasib **0**
- Datopotamab deruxtecan **0**
- Amivantamab with Lazertinib **0**

Q2. Does your trust participate in any clinical trials for Non-Small Cell Lung Cancer?
If so, please provide the name of each trial, and the number of patients taking part.

We are open to the following trials for Non-Small Cell Lung Cancer and number of patients:

Be6A Lung-02 - 0

CodeBreak 202 - 1

eVOLVE-Lung02 - 2

MK3475A-F84 - 0

PACIFIC-8 - 0

TROPION-Lung01 - 0

REFINE-Lung - 3, but not on treatment

Attachment(s):

No Attachment(s)

Date Response sent: 29 October 2025

